Dr. Pieter Cullis

Director, Nanomedicines Research Group and Professor, Department of Biochemistry and Molecular Biology

University of British Columbia

Yellow topographic lines in circle.

About Dr. Pieter Cullis

Pieter R. Cullis, PhD, FRSC, FNAI (USA), OC, Director, Nanomedicines Research Group, Professor, Department of Biochemistry and Molecular Biology, University of British Columbia. Dr. Cullis and co-workers have been responsible for fundamental advances in the development of nanomedicines employing lipid nanoparticle (LNP) technology for cancer therapies, gene therapies and vaccines. This work has contributed to five drugs that have received clinical approval by the FDA, the European EMA and Health Canada.
Dr. Cullis has also co-founded eleven biotechnology companies that now employ over 400 people, has published over 350 scientific articles (h index 129) and is an inventor on over 100 patents. He has also co-founded and been Founding Scientific Director of two National Centre of Excellence networks, the Centre for Drug Research and Development (now AdMare) in 2004 and the NanoMedicines Innovation Network in 2019.
These not-for-profit networks are aimed at translating basic research in the life sciences into commercially viable products and have given rise to numerous start-up companies. Dr. Cullis has received many awards including the Order of Canada in 2021 and the VinFuture Prize (Vietnam), the Prince Mahidol Award (Thailand), the Gairdner International Award (Canada) and the Tang Prize (Taiwan) in 2022. Two recently approved drugs that are enabled by LNP delivery systems devised by Dr. Cullis, members of his UBC laboratory and colleagues in the companies he has co-founded deserve special emphasis. The first is Onpattro which was approved by the US FDA in August 2018 to treat the previously fatal hereditary condition transthyretin-induced amyloidosis (hATTR). Onpattro is the first RNAi drug to receive regulatory approval.
The second is Comirnaty, the COVID-19 mRNA vaccine developed by Pfizer/BioNTech that has received regulatory approval in many jurisdictions including Canada, the USA, the UK and Europe. Comirnaty is playing a major role in containing the global Covid-19 pandemic with approximately 3B doses administered worldwide in 2021.
Speaking at...
Mentorship Session | Dr. Pieter Cullis
Mentorship Session | Dr. Pieter Cullis
April 15, 2023
April 15, 2023 09:30 –
12:30 PDT
Dr. Pieter Cullis
The Gairdner Symposium
Gairdner Symposium (Speakers 1 & 2)
April 14, 2023
April 14, 2023 10:00 –
11:30 PDT
Dr. Pieter Cullis, Dr. Quarraisha Abdool Karim

Attend ICAM 2024!

Don’t wait to reserve your spot at this leading international gathering dedicated to academic medicine.